Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis

Table 1 Pretreatment clinical characteristics categorized according to treatment administered to 156 patients with high-risk prostate cancer, adjusted for propensity scores

Pretreatment characteristics	Radiation therapy (N = 78)	Radical prostatectomy (N = 78)	P
Age (year, median)	73.5	71	0.0633^a
Initial prostate-specific antigen level (ng/mL, median)	21.42	20.00	0.3886
Clinical T stage
T1c	19	22	0.8482
T2	23	19	0.8482
T3	36	37
Biopsy Gleason score
≤6	5	4	0.9384
7	24	23	0.9384
≥8	49	51
Follow-up period (month, median)	37.6	31.5	0.3338

ISSN: 1477-7819